Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CURLF NASDAQ:LEGN NASDAQ:RVMD NASDAQ:RYTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCURLFCuraleaf$2.50-13.8%$1.34$0.68▼$3.58$1.94B0.691.86 million shs1.71 million shsLEGNLegend Biotech$36.54-2.4%$37.89$27.34▼$59.62$6.88B0.261.12 million shs703,937 shsRVMDRevolution Medicines$36.54+0.2%$37.74$29.17▼$62.40$6.81B1.161.86 million shs2.00 million shsRYTMRhythm Pharmaceuticals$97.19-0.9%$79.69$43.57▼$99.04$6.52B2.38566,562 shs349,469 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCURLFCuraleaf-13.79%-8.09%+150.00%+199.33%-24.92%LEGNLegend Biotech-2.43%-1.22%-12.14%+28.98%-35.84%RVMDRevolution Medicines+0.25%+3.63%-4.60%-5.68%-16.29%RYTMRhythm Pharmaceuticals-0.92%+0.76%+8.96%+55.73%+106.35%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCURLFCuraleaf0.7531 of 5 stars0.04.00.00.02.30.00.6LEGNLegend Biotech3.7406 of 5 stars4.54.00.00.02.51.70.6RVMDRevolution Medicines4.2645 of 5 stars4.51.00.04.72.61.70.0RYTMRhythm Pharmaceuticals3.7338 of 5 stars2.53.00.04.33.20.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCURLFCuraleaf 4.00Strong BuyN/AN/ALEGNLegend Biotech 3.00Buy$72.3898.07% UpsideRVMDRevolution Medicines 3.00Buy$69.9291.36% UpsideRYTMRhythm Pharmaceuticals 3.07Buy$101.574.51% UpsideCurrent Analyst Ratings BreakdownLatest CURLF, LEGN, RVMD, and RYTM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025RVMDRevolution MedicinesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight$75.008/18/2025RVMDRevolution MedicinesLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$80.008/15/2025RVMDRevolution MedicinesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$67.008/12/2025LEGNLegend BiotechRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$75.00 ➝ $77.008/12/2025LEGNLegend BiotechMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$81.00 ➝ $83.008/8/2025CURLFCuraleafCormarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Moderate Buy8/7/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$57.00 ➝ $56.008/7/2025RYTMRhythm PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$80.00 ➝ $100.008/6/2025RYTMRhythm PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$119.00 ➝ $120.008/6/2025RYTMRhythm PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$130.00 ➝ $135.008/5/2025RYTMRhythm PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$100.00 ➝ $109.00(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCURLFCuraleaf$1.34B1.25$0.18 per share14.27$1.30 per share1.92LEGNLegend Biotech$627.24M10.70N/AN/A$5.64 per share6.48RVMDRevolution Medicines$11.58M589.85N/AN/A$9.98 per share3.66RYTMRhythm Pharmaceuticals$130.13M49.61N/AN/A($0.18) per share-539.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCURLFCuraleaf-$215.42M-$0.32N/AN/AN/A-18.08%-14.61%-4.47%N/ALEGNLegend Biotech-$177.03M-$0.88N/AN/AN/A-40.83%-32.00%-20.07%N/ARVMDRevolution Medicines-$600.09M-$4.50N/AN/AN/AN/A-41.78%-35.63%11/5/2025 (Estimated)RYTMRhythm Pharmaceuticals-$260.60M-$3.01N/AN/AN/A-117.13%-1,831.43%-48.33%11/4/2025 (Estimated)Latest CURLF, LEGN, RVMD, and RYTM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025LEGNLegend Biotech-$0.22-$0.34-$0.12-$0.34$237.49 million$255.06 million8/6/2025Q2 2025CURLFCuraleaf-$0.07-$0.06+$0.01-$0.07N/AN/A8/6/2025Q2 2025RVMDRevolution Medicines-$0.94-$1.31-$0.37-$1.31$0.50 millionN/A8/5/2025Q2 2025RYTMRhythm Pharmaceuticals-$0.66-$0.75-$0.09-$0.75$43.72 million$48.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCURLFCuraleafN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCURLFCuraleaf1.001.470.70LEGNLegend Biotech0.304.714.57RVMDRevolution Medicines0.1311.7911.79RYTMRhythm PharmaceuticalsN/A2.792.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCURLFCuraleaf0.03%LEGNLegend Biotech70.89%RVMDRevolution Medicines94.34%RYTMRhythm PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCURLFCuraleafN/ALEGNLegend Biotech0.02%RVMDRevolution Medicines8.20%RYTMRhythm Pharmaceuticals6.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCURLFCuraleaf5,519670.46 millionN/ANot OptionableLEGNLegend Biotech2,609183.76 million183.73 millionOptionableRVMDRevolution Medicines250186.93 million171.60 millionOptionableRYTMRhythm Pharmaceuticals14066.42 million62.37 millionOptionableCURLF, LEGN, RVMD, and RYTM HeadlinesRecent News About These CompaniesLord Abbett & CO. LLC Has $7.17 Million Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)August 19 at 5:17 AM | marketbeat.comPNC Financial Services Group Inc. Boosts Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)August 18 at 3:16 AM | marketbeat.comFox Run Management L.L.C. Makes New Investment in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)August 17 at 6:11 AM | marketbeat.comE Fund Management Co. Ltd. Makes New $286,000 Investment in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)August 17 at 5:23 AM | marketbeat.comInsider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Sells 1,500 Shares of StockAugust 16, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CFO Sells $333,792.00 in StockAugust 16, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CFO Hunter C. Smith Sells 24,611 SharesAugust 16, 2025 | marketbeat.com5,502 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Acquired by Entropy Technologies LPAugust 16, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Increases Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)August 16, 2025 | marketbeat.comJoseph Shulman Sells 3,984 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) StockAugust 15, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Joseph Shulman Sells 3,984 SharesAugust 14, 2025 | insidertrades.comInformed Momentum Co LLC Sells 17,970 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)August 14, 2025 | marketbeat.com7,701 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Purchased by Aigen Investment Management LPAugust 14, 2025 | marketbeat.comRhythm Pharmaceuticals’ RM-718 Study: A Potential Game-Changer in Obesity TreatmentAugust 14, 2025 | msn.comRhythm Pharmaceuticals (NASDAQ:RYTM) Sets New 1-Year High - What's Next?August 13, 2025 | marketbeat.comPersistent Asset Partners Ltd Sells 6,811 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)August 13, 2025 | marketbeat.comGuggenheim Keeps Their Buy Rating on Rhythm Pharmaceuticals (RYTM)August 13, 2025 | theglobeandmail.comAnalysts Are Bullish on Top Healthcare Stocks: Rhythm Pharmaceuticals (RYTM), Krystal Biotech (KRYS)August 13, 2025 | theglobeandmail.comHC Wainwright Brokers Increase Earnings Estimates for RYTMAugust 11, 2025 | marketbeat.comLeerink Partnrs Has Positive Outlook of RYTM Q3 EarningsAugust 10, 2025 | americanbankingnews.comLeerink Partners Keeps Their Buy Rating on Rhythm Pharmaceuticals (RYTM)August 9, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCURLF, LEGN, RVMD, and RYTM Company DescriptionsCuraleaf OTCMKTS:CURLF$2.50 -0.40 (-13.79%) As of 08/19/2025 04:00 PM EasternCuraleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.Legend Biotech NASDAQ:LEGN$36.54 -0.91 (-2.43%) Closing price 08/19/2025 04:00 PM EasternExtended Trading$36.62 +0.08 (+0.21%) As of 08/19/2025 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Revolution Medicines NASDAQ:RVMD$36.54 +0.09 (+0.25%) Closing price 08/19/2025 04:00 PM EasternExtended Trading$36.55 +0.01 (+0.03%) As of 08/19/2025 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Rhythm Pharmaceuticals NASDAQ:RYTM$97.19 -0.90 (-0.92%) Closing price 08/19/2025 04:00 PM EasternExtended Trading$97.44 +0.25 (+0.25%) As of 08/19/2025 05:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Home Depot Holds Gains After Narrow Q2 Misses Medtronic: The Opportunity Gets Healthier for Income Investors Palo Alto Networks Uptrend Confirmed! New Highs Set by Year’s End Micron Stock Still Cheap Despite 25% Rally, Analysts Say Qualcomm Just Passed 1 Major Test, But Can It Pass the Next? DLocal Stock Soars 43% After Earnings Beat and Raised Guidance D-Wave Buying Spree: Will These Firms Be Potential Targets? Lyft's Billion-Dollar Signal: Why Wall Street Is Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access